



UW PACC

Psychiatry and Addictions Case Conference

UW Medicine | Psychiatry and Behavioral Sciences

ANTIPSYCHOTIC USE IN GERIATRIC PATIENTS: SHOULD I USE THEM IN PATIENTS WITHOUT PSYCHOSIS?

WHITNEY CARLSON, MD

**HARBORVIEW MENTAL HEALTH AND ADDICTION
SERVICES**



GENERAL DISCLOSURES

The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State.

GENERAL DISCLOSURES

UW PACC is also supported by Coordinated Care
of Washington

SPEAKER DISCLOSURES

Dr. Carlson has no relevant conflicts of interest to disclose.

PLANNER DISCLOSURES

The following series planners have no relevant conflicts of interest to disclose:

Mark Duncan MD

Barb McCann PhD

Rick Ries MD

Kari Stephens PhD

Cameron Casey

Betsy Payn

Diana Roll

Cara Towle MSN RN

Anna Ratzliff MD PhD has received book royalties from John Wiley & Sons (publishers).

UW PACC REGISTRATION

Please be sure that you have completed the full UW PACC series registration.

If you have not yet registered, please email uwpacc@uw.edu so we can send you a link.

OBJECTIVES

1. Discuss major indications for using antipsychotics for non-psychotic symptoms in older adults
2. Discuss common side effects in older adults and FDA black box warning
3. Discuss relative choice of antipsychotic based on patient profile

ABBREVIATIONS

- BPAD = bipolar affective disorder
- MDD = major depressive disorder
- SGA = second generation antipsychotic
- SNF = skilled nursing facility
- CKD = chronic kidney disease
- EPS = extrapyramidal symptoms
- TD = tardive dyskinesia

CASE

- 70 year old woman long history of BPAD
- Recent episode of lithium toxicity, CKD
- Started on valproic acid as mood stabilizer
- Diabetes and CAD among medical issues
- 12 chronic medications
- Ongoing mixed symptoms
- Mild cognitive impairment prior to episode

BURDEN OF ANTIPSYCHOTICS

- In the U.S.
 - 26% of antipsychotic prescriptions for schizophrenia and BPAD were for age >65
 - >2% patients aged 80 to 84 receiving antipsychotics
 - 54% patients aged 70 to 74 prescribed for >120 days
 - 88% of Medicare claims for SGAs in SNFs associated with dementia diagnosis
- Satovic M et al, Prescribing Antipsychotics in Geriatric Patients, Current Psychiatry Oct-Dec 2017

2005 FDA BLACK BOX WARNING ANTIPSYCHOTICS

- increased risk of death in elderly patients **with dementia**
- applies to both SGAs and first generation antipsychotics
- “spillover effect” —decreased use of SGAs for FDA approved indications even for younger

WHAT ARE FDA APPROVED INDICATIONS FOR SGAS?

- BPAD: mania/mixed
- BPAD: depression
- BPAD: maintenance
- MDD: monotherapy
- MDD: antidepressant augmentation
- MDD: with psychosis
- Schizophrenia
- Schizoaffective disorder

ADDITIONAL POSSIBLE USES—OFF LABEL

- Augmentation in OCD
 - Response in 1/3 SSRI resistant cases
 - 1st line augmenting agents OCD
 - risperidone and aripiprazole favored
- PTSD
 - May help with sleep/comorbid depression symptoms
 - Not first line—would be augmentation
- Dementia with significant behavioral disturbance
 - Non pharmacologic options best
 - aggression, placement-threatening, quick response needed
 - Lowest effective dose
 - Time limited
 - Document discussion of risks

SGAS IN BIPOLAR DISORDER

	Mania/mixed	Depression
aripiprazole (Abilify)	x	
asenapine (Sycrest)	x	
cariprazine (Vraylar)	x	x
lurasidone (Latuda)	x	x
olanzapine (Zyprexa) (with fluoxetine for depr.)	x	x
quetiapine (Seroquel)	x	x
risperidone (Risperdal)	x	
ziprasidone (Geodon)	x	

DATA IS LIMITED

- No prospective controlled studies in BPAD
- Does clinical effectiveness=long term safety
- Studies lack “real world” older adult patients
- Impact of long term use of SGAs vs. alternative agents on brain health

ANTIDEPRESSANT AUGMENTATION

- olanzapine (Zyprexa)
- quetiapine (Seroquel)---IR or XR
- aripiprazole (Abilify)
- brexpiprazole (Rexulti)

CLINICAL CONSIDERATIONS

- Medical comorbidities
 - Dementia
 - Diabetes
 - Parkinson's disease/parkinsonism
- Fall risk
- Other QTc prolonging medications
- Orthostatic hypotension
- Cost

ADVERSE EFFECTS MORE COMMON IN OLDER ADULTS

- EPS/TD
- Postural hypotension → falls/fractures
- Anticholinergic → constipation, urinary retention, cognitive
- Antihistaminic → sedation, dry mouth
- Cardiovascular → QTc prolongation, stroke, arrhythmia
- Metabolic
- Hematologic → reduced WBC/platelets, bleeding

GENERAL PRESCRIBING SUGGESTIONS

- Match choice given comorbidities/symptom profile
- Start low
- Titrate slowly
- Use lowest effective dose
- Evaluate often for EPS and TD—dose reduction
- Metabolic monitoring
- Long term: monitor cognition, dose reduction?

WHAT WOULD YOU RECOMMEND FOR OUR EARLIER CASE?

- Consider
 - Diabetes/CAD
 - Mixed symptoms (depression, ongoing hypomania/mania)
 - Sleep disturbance vs. sedation
 - Orthostasis
 - Short term or maintenance use likely

THINGS I CONSIDER AS A GERIATRICIAN

- One medication to cover as many symptoms as possible
- Non-antipsychotic options I haven't considered
- Medical issues that are most likely to limit other choices
- Patient side effect concerns/cost limitations
- Relapse history/hospitalizations/suicide risk

REFERENCES

- Gareri P, Segura-Garcia C, Manfredi V et al. Use of atypical antipsychotics in the elderly: a clinical review. *Clinical Interventions in Aging*. 2014; 9: 1363-1373
- Kales H, Sajatovic M, and Mulsant B. Prescribing antipsychotics in geriatric patients: Focus on dementia. *Current Psychiatry*. 2017; 16(12): 24-30
- Mulsant B, Kales, H, and Sajatovic M. Prescribing antipsychotics in geriatric patients: Focus on major depressive disorder. *Current Psychiatry*. 2017; 16 (11): 21-27
- Sajatovic M, Kales H, and Mulsant B. Prescribing antipsychotics in geriatric patients: Focus on schizophrenia and bipolar disorder. *Current Psychiatry*. 2017; 16(10):20-26,28
- Sajatovic M and Chen P. Geriatric Bipolar Disorder. *Psychiatr Clin N Am*. 2011; 34: 319-333